FDA
-
-
-
-
-
-
-
Meridian Bioscience (VIVO) Receives FDA-Clearance for the Curian Campy Assay
-
-
-
-
-
-
-
Meridian Bioscience Reports Third Quarter Fiscal 2021 Results
-
-
-
-
-
-
-
Meridian Bioscience Reports Strong Growth in Net Revenues and EPS in Second Quarter Fiscal 2021
-
-
-
-
-
-
-
Meridian Bioscience Provides a Further Update on the Revogene® SARS-CoV-2 EUA Submission
-
-
-
-
-
-
-
Meridian Bioscience Expands Production Capacity with Support from NIH, JobsOhio, and the Village of Newtown
-
-
-
-
-
-
-
Meridian Bioscience receives NIH Award for supporting rapid development of Revogene® molecular test for SARS-CoV-2
-
-
-
-
-
-
-
Meridian Bioscience Reports Fiscal Third Quarter 2020 Operating Results – Best Quarter in Company History – Raises Full Year Guidance
-
251,761 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All